Ensysce Biosciences, Inc. (ENSC)
ENSC moved a median of -0.91% 30 minutes after news, and -0.80% by the close. How ENSC actually reacts to news — the realized, point-in-time move the market made, measured across 225 labeled events over the last three years with zero look-ahead.
ENSC’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 36% | 216 |
| 30-min | -0.91% | 36% | 222 |
| 60-min | -0.19% | 45% | 224 |
| to close | -0.80% | 45% | 222 |
| Middle 50% of ENSC reactions | -2.57% to +1.24% |
|---|---|
| Median reaction (30-min) | -0.91% |
| Measured reactions | 225 |
Half of all Ensysce Biosciences, Inc. news events land between -2.57% and +1.24% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when ENSC moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to ENSC's baseline. Nothing else.
Recent ENSC events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K/A Ensysce Biosciences, For: Aug 05 | SEC filing · Form 8-K | SEC EDGAR | -1.40% | -11.72% | |
| Form 8-K Ensysce Biosciences, For: Sep 25 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +3.22% | |
| Ensysce Biosciences Phase 2 Protocol for CY200 - A Neuroplastigen for the Treatment of CRPS - Submitted to the UK MHRA | Press release | ACCESS Newswire | -3.71% | -6.04% | |
| Ensysce Biosciences Advances CRPS Program at Painweek 2026, Contributes to FDA Hearing on Psychedelic Drug Regulation | Press release | ACCESS Newswire | -3.09% | -5.07% | |
| Ensysce Biosciences' Professor Richard Langford Selected to Speak at FDA Public Hearing on the Potential Future Therapeutic Use of Psychedelic Drugs | Press release | ACCESS Newswire | -0.60% | -1.75% | |
| Ensysce Biosciences Announces Upcoming Conference and Industry Event Participation | Press release | ACCESS Newswire | -1.38% | +10.70% | |
| Ensysce Biosciences Completes Final Phase of PF614-MPAR-102 Clinical Study | Press release | ACCESS Newswire | +0.37% | +0.69% | |
| Form 8-K Ensysce Biosciences, For: Aug 25 | SEC filing · Form 8-K | SEC EDGAR | +0.27% | +0.49% | |
| Form 8-K Ensysce Biosciences, For: Aug 24 | SEC filing · Form 8-K | SEC EDGAR | +1.91% | +11.63% | |
| Ensysce Biosciences to Showcase "A New Era in Pain Therapeutics" at PAINWeek 2026 Symposium | Press release | ACCESS Newswire | +1.58% | -0.66% | |
| Form D Ensysce Biosciences, | SEC filing · Form D | SEC EDGAR | +0.01% | +3.89% | |
| Ensysce Biosciences Reports Second Quarter 2026 Financial Results and Recent Business Highlights | Press release | ACCESS Newswire | +1.59% | +17.93% | |
| Form 10-Q Ensysce Biosciences, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +1.59% | +17.93% | |
| Form 8-K Ensysce Biosciences, For: Aug 13 | SEC filing · Form 8-K | SEC EDGAR | +1.59% | +17.93% | |
| Ensysce Biosciences Announces Acquisition of Cy Biopharma and up to $77 Million Private Financing | Press release | ACCESS Newswire | -5.45% | -18.08% | |
| Form 8-K Ensysce Biosciences, For: Aug 05 | SEC filing · Form 8-K | SEC EDGAR | -5.45% | -18.08% | |
| Form 8-K/A Ensysce Biosciences, For: Aug 05 | SEC filing · Form 8-K | SEC EDGAR | -1.35% | +0.81% | |
| Form 8-K Ensysce Biosciences, For: Jul 15 | SEC filing · Form 8-K | SEC EDGAR | -1.43% | -3.08% | |
| Ensysce Biosciences Awarded $5.3 Million Installment in NIDA Funding Completing Multi-Year $15 Million Federal Grant | Press release | ACCESS Newswire | -3.33% | +12.11% | |
| Form EFFECT Ensysce Biosciences, | SEC filing · Form EFFECT | SEC EDGAR | +0.00% | -1.10% | |
| Ensysce Biosciences Enrolls First Patient in Final Phase of PF614-MPAR-102 Clinical Study | Press release | ACCESS Newswire | -1.48% | +6.21% | |
| Form S-3 Ensysce Biosciences, | SEC filing · Form S-3 | SEC EDGAR | -1.54% | -2.27% | |
| Form 8-K Ensysce Biosciences, For: May 22 | SEC filing · Form 8-K | SEC EDGAR | +0.61% | -1.41% | |
| Ensysce Biosciences Reports First Quarter 2026 Financial Results | Press release | ACCESS Newswire | -4.33% | +24.90% | |
| Form 10-Q Ensysce Biosciences, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -4.33% | +24.90% | |
| Form 8-K Ensysce Biosciences, For: May 15 | SEC filing · Form 8-K | SEC EDGAR | -4.33% | +24.90% | |
| Ensysce Biosciences Announces Expansion of Patent Protection for Groundbreaking MPAR(R) Overdose Protection Technology | Press release | ACCESS Newswire | +0.85% | -4.35% | |
| Ensysce Biosciences CEO Presents at Inaugural Clinical Pain Symposium in Amsterdam | Press release | ACCESS Newswire | -0.77% | -6.61% | |
| Form S-8 Ensysce Biosciences, | SEC filing · Form S-8 | SEC EDGAR | -2.39% | +2.15% | |
| Ensysce Biosciences Secures IRB Approval of Final Phase of PF614-MPAR-102 Clinical Study | Press release | ACCESS Newswire | -4.08% | -6.37% | |
| Form EFFECT Ensysce Biosciences, | SEC filing · Form EFFECT | SEC EDGAR | -4.08% | -6.37% | |
| Form S-3 Ensysce Biosciences, | SEC filing · Form S-3 | SEC EDGAR | -0.40% | -3.59% | |
| Form 8-K Ensysce Biosciences, For: Apr 07 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -13.76% | |
| Ensysce Biosciences Secures Second Financing From 2025 Agreement to Advance Breakthrough Pain Programs | Press release | ACCESS Newswire | +0.23% | +2.88% | |
| Form 8-K Ensysce Biosciences, For: Apr 03 | SEC filing · Form 8-K | SEC EDGAR | +0.38% | -3.67% | |
| Ensysce Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results | Press release | ACCESS Newswire | -1.71% | +6.91% | |
| Form 10-K Ensysce Biosciences, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -1.71% | +6.91% | |
| Form 8-K Ensysce Biosciences, For: Mar 27 | SEC filing · Form 8-K | SEC EDGAR | -5.55% | -4.99% | |
| Form 8-K Ensysce Biosciences, For: Mar 30 | SEC filing · Form 8-K | SEC EDGAR | -1.71% | +6.91% | |
| Form 8-K Ensysce Biosciences, For: Mar 23 | SEC filing · Form 8-K | SEC EDGAR | -0.02% | +2.67% | |
| Ensysce Biosciences Initiates Live "Ask Me Anything" (AMA) Session Highlighting Growth and Future Plans | Press release | ACCESS Newswire | -2.25% | +2.33% | |
| Ensysce Biosciences Announces First Peer-Reviewed Clinical Publication Demonstrating Oral Overdose Protection with MPAR(R) Technology | Press release | ACCESS Newswire | -0.88% | -12.07% | |
| Form 8-K Ensysce Biosciences, For: Feb 27 | SEC filing · Form 8-K | SEC EDGAR | +12.82% | +20.94% | |
| Ensysce Biosciences Initiates Review of Strategic Alternatives to Enhance Shareholder Value | Press release | ACCESS Newswire | -2.42% | -1.17% | |
| Ensysce Biosciences Invited to Participate in Upcoming Scientific and Industry Events | Press release | ACCESS Newswire | -3.10% | +0.60% | |
| Ensysce Biosciences Provides Enrollment Update on Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid for Severe Acute Pain | Press release | ACCESS Newswire | +0.48% | -6.27% | |
| Ensysce Biosciences Expands Global Opioid Patent Portfolio | Press release | ACCESS Newswire | +0.00% | -0.21% | |
| Ensysce Biosciences Receives EU Patent Expanding its First-in-Class ADHD Therapy with Built-In Abuse and Overdose Protection | Press release | ACCESS Newswire | +0.00% | -3.64% | |
| Form 8-K Ensysce Biosciences, For: Jan 08 | SEC filing · Form 8-K | SEC EDGAR | -1.35% | -8.11% | |
| Ensysce Biosciences Issues Annual Shareholder Letter | Press release | ACCESS Newswire | +0.00% | +9.47% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the ENSC section they belong to.
Where else ENSC is measured.
ENSC earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Ensysce Biosciences, Inc.'s median reaction calculated?
Every labeled ENSC news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 225 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 36% of ENSC's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does ENSC's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.